These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 27751704)

  • 1. When Hydromorphone Is Not Working, Try Loratadine: An Emergency Department Case of Loratadine as Abortive Therapy for Severe Pegfilgrastim-Induced Bone Pain.
    Moore K; Haroz R
    J Emerg Med; 2017 Feb; 52(2):e29-e31. PubMed ID: 27751704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe pegfilgrastim-induced bone pain completely alleviated with loratadine: A case report.
    Romeo C; Li Q; Copeland L
    J Oncol Pharm Pract; 2015 Aug; 21(4):301-4. PubMed ID: 24664474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can loratadine help in treating granulocyte-colony stimulating factor-induced bone pain?
    Gajarawala SN; Pelkowski JN; DeStephano CC
    JAAPA; 2021 Jul; 34(7):29-31. PubMed ID: 34162806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim.
    Moukharskaya J; Abrams DM; Ashikaga T; Khan F; Schwartz J; Wilson K; Verschraegen C; Openshaw T; Valentine J; Eneman J; Unger P; Ades S
    Support Care Cancer; 2016 Jul; 24(7):3085-93. PubMed ID: 26894485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim.
    Kirshner JJ; McDonald MC; Kruter F; Guinigundo AS; Vanni L; Maxwell CL; Reiner M; Upchurch TE; Garcia J; Morrow PK
    Support Care Cancer; 2018 Apr; 26(4):1323-1334. PubMed ID: 29147854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade.
    Gavioli E; Abrams M
    Support Care Cancer; 2017 Mar; 25(3):817-822. PubMed ID: 27817104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral loratadine in the management of G-CSF-induced bone pain: a pilot study.
    Duggan C; Murphy L; Costello V; Leary EO; Yousif AD; Blazkova S; Dowling M
    Br J Nurs; 2019 Feb; 28(4):S4-S11. PubMed ID: 30811242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs).
    Lambertini M; Del Mastro L; Bellodi A; Pronzato P
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):112-28. PubMed ID: 24041627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience.
    Renwick W; Pettengell R; Green M
    BioDrugs; 2009; 23(3):175-86. PubMed ID: 19627169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
    Heaney ML; Toy EL; Vekeman F; Laliberté F; Dority BL; Perlman D; Barghout V; Duh MS
    Cancer; 2009 Oct; 115(20):4839-48. PubMed ID: 19637341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes.
    Yang BB; Savin MA; Green M
    Chemotherapy; 2012; 58(5):387-98. PubMed ID: 23296266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.
    Petru E; Singer CF; Polterauer S; Galid A; Schauer C; Klocker J; Seifert M; Reinthaller A; Benedicic C; Hubalek M; Hefler L; Marth C; Scholl-Firon T; Bogner G; Zeimet AG
    Wien Med Wochenschr; 2015 Oct; 165(19-20):387-94. PubMed ID: 26471371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia.
    Aapro M; Cornes P; Abraham I
    J Oncol Pharm Pract; 2012 Jun; 18(2):171-9. PubMed ID: 21610020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Loratadine for Pegfilgrastim-Induced Bone Pain.
    Mazzola J; Hennon P; Peine K; Siedlecki SL
    Pain Manag Nurs; 2024 Apr; 25(2):e132-e137. PubMed ID: 38216368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
    Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
    Ricotta R; Cerea G; Schiavetto I; Maugeri MR; Pedrazzoli P; Siena S
    Future Oncol; 2006 Dec; 2(6):667-76. PubMed ID: 17155894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed hypersensitivity reaction related to the use of pegfilgrastim.
    Dadla A; Tannenbaum S; Yates B; Holle L
    J Oncol Pharm Pract; 2015 Dec; 21(6):474-7. PubMed ID: 24993705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
    Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
    Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N
    Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.